SGLT2抑制剂对急性心肌梗死合并2型糖尿病患者心功能的影响研究进展
Research Progress on the Effect of SGLT2 Inhibitors on Cardiac Function in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus
DOI: 10.12677/acm.2025.1551502, PDF,   
作者: 齐心源：承德医学院研究生学院，河北 承德；马利祥*：秦皇岛市第一医院心血管内科，河北 秦皇岛
关键词: 钠葡萄糖耦联转运体2抑制剂；急性心肌梗死；2型糖尿病；心功能；Sodium-Glucose Linked Transporter 2 Inhibitors； Acute Myocardial Infarction； Type 2 Diabetes Mellitus； Cardiac Function
摘要: 急性心肌梗死(acute myocardial infarction, AMI)是一种严重的心血管急症，AMI患者病死率高、预后差，AMI合并糖尿病患者预后更差。钠葡萄糖耦联转运体2 (sodium-glucose linked transporter 2, SGLT2)抑制剂是首个具有心血管保护作用的降糖药，越来越多的临床研究显示SGLT2抑制剂可以改善AMI合并糖尿病患者的心血管预后，目前SGLT2抑制剂在AMI合并2型糖尿病(Type 2 diabetes mellitus, T2DM)的心血管获益机制尚不明确，本文就SGLT2抑制剂在AMI合并T2DM的作用机制、影响心功能指标及预后方面进行综述。
Abstract: Acute myocardial infarction (AMI) is a serious cardiovascular emergency. AMI patients have a high mortality and a poor prognosis, and AMI patients with diabetes have a worse prognosis. Sodium-glucose linked transporter 2 (SGLT2) inhibitors are the first anti-diabetic drugs with cardiovascular protective effects. More and more clinical studies have shown that SGLT2 inhibitors can improve the cardiovascular prognosis of patients with acute myocardial infarction and diabetes. At present, the cardiovascular benefit mechanism of SGLT2 inhibitors in acute myocardial infarction complicated with type 2 diabetes is not clear. This article reviews the mechanism of SGLT2 inhibitors in acute myocardial infarction complicated with type 2 diabetes, and its effect on cardiac function indexes and prognosis.
文章引用：齐心源, 马利祥. SGLT2抑制剂对急性心肌梗死合并2型糖尿病患者心功能的影响研究进展[J]. 临床医学进展, 2025, 15(5): 1359-1364. https://doi.org/10.12677/acm.2025.1551502

参考文献

[1] 冉雪, 樊落, 马晓艳, 等. 我国急性心肌梗死病人死亡危险因素的Meta分析[J]. 循证护理, 2022, 8(7): 885-891.
[2] 国家心血管病中心, 中国心血管健康与疾病报告编写组, 胡盛寿. 中国心血管健康与疾病报告2023概要[J]. 中国循环杂志, 2024, 39(7): 625-660.
[3] 邓伏雪, 王小娟, 胡云凤, 等. 急性心肌梗死并发首次心力衰竭患者在院死亡率及临床预后分析[J]. 西安交通大学学报(医学版), 2015, 36(1): 135-140.
[4] 蓝淦秋, 于佳雪, 陈利华, 等. 达格列净对经皮冠状动脉介入治疗后急性心肌梗死合并2型糖尿病患者的心功能和预后影响[J]. 心血管病防治知识, 2024, 14(14): 41-45+49.
[5] McDonagh, T.A., Metra, M., Adamo, M., Gardner, R.S., Baumbach, A., Böhm, M., et al. (2021) 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal, 42, 3599-3726. [Google Scholar] [CrossRef] [PubMed]
[6] 刘铭彦, 张冰琪, 李虎虎, 等. 钠-葡萄糖共转运蛋白2抑制剂治疗2型糖尿病合并射血分数保留心力衰竭的研究状况[J]. 中国临床药理学杂志, 2024, 40(13): 1977-1981.
[7] Maliha, G. and Townsend, R.R. (2015) SGLT2 Inhibitors: Their Potential Reduction in Blood Pressure. Journal of the American Society of Hypertension, 9, 48-53. [Google Scholar] [CrossRef] [PubMed]
[8] Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 373, 2117-2128. [Google Scholar] [CrossRef] [PubMed]
[9] Paolisso, P., Foà, A., Bergamaschi, L., Donati, F., Fabrizio, M., Chiti, C., et al. (2021) Hyperglycemia, Inflammatory Response and Infarct Size in Obstructive Acute Myocardial Infarction and MINOCA. Cardiovascular Diabetology, 20, Article No. 33. [Google Scholar] [CrossRef] [PubMed]
[10] Algoet, M., Janssens, S., Himmelreich, U., Gsell, W., Pusovnik, M., Van den Eynde, J., et al. (2023) Myocardial Ischemia-Reperfusion Injury and the Influence of Inflammation. Trends in Cardiovascular Medicine, 33, 357-366. [Google Scholar] [CrossRef] [PubMed]
[11] Lee, T., Chang, N. and Lin, S. (2017) Dapagliflozin, a Selective SGLT2 Inhibitor, Attenuated Cardiac Fibrosis by Regulating the Macrophage Polarization via STAT3 Signaling in Infarcted Rat Hearts. Free Radical Biology and Medicine, 104, 298-310. [Google Scholar] [CrossRef] [PubMed]
[12] 帕丽达·玉山江, 尼格热·阿力木, 吐尔孙阿依·依斯提米拉, 等. 单核细胞亚群与急性心肌梗死相关研究进展[J]. 新疆医学, 2024, 54(6): 715-717+721.
[13] Paolisso, P., Bergamaschi, L., Santulli, G., Gallinoro, E., Cesaro, A., Gragnano, F., et al. (2022) Infarct Size, Inflammatory Burden, and Admission Hyperglycemia in Diabetic Patients with Acute Myocardial Infarction Treated with SGLT2-Inhibitors: A Multicenter International Registry. Cardiovascular Diabetology, 21, Article No. 77. [Google Scholar] [CrossRef] [PubMed]
[14] 陈佩玲, 杨柳, 安玉, 等. 钠-葡萄糖协同转运蛋白2抑制剂的心血管保护机制及临床研究进展[J]. 肾脏病与透析肾移植杂志, 2022, 31(4): 357-362.
[15] Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., et al. (2016) Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects without Diabetes and Patients with Type 2 Diabetes. Diabetes, 65, 1190-1195. [Google Scholar] [CrossRef] [PubMed]
[16] Lindsay, R.T., Dieckmann, S., Krzyzanska, D., Manetta-Jones, D., West, J.A., Castro, C., et al. (2021) β-Hydroxybutyrate Accumulates in the Rat Heart during Low-Flow Ischaemia with Implications for Functional Recovery. eLife, 10, e71270. [Google Scholar] [CrossRef] [PubMed]
[17] Perry, R.J. and Shulman, G.I. (2020) Sodium-Glucose Cotransporter-2 Inhibitors: Understanding the Mechanisms for Therapeutic Promise and Persisting Risks. Journal of Biological Chemistry, 295, 14379-14390. [Google Scholar] [CrossRef] [PubMed]
[18] Verma, S., Rawat, S., Ho, K.L., Wagg, C.S., Zhang, L., Teoh, H., et al. (2018) Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational In-Sights into the Heart Failure Benefits of SGLT2 Inhibitors. JACC: Basic to Translational Science, 3, 575-587. [Google Scholar] [CrossRef] [PubMed]
[19] van der Kooij, S.M., Hehenkamp, W.J.K., Birnie, E., Ankum, W.M., Mol, B.W., Scherjon, S., et al. (2013) The Effect of Treatment Preference and Treatment Allocation on Patients’ Health-Related Quality of Life in the Randomized EMMY Trial. European Journal of Obstetrics & Gynecology and Reproductive Biology, 169, 69-74. [Google Scholar] [CrossRef] [PubMed]
[20] Li, X., Lu, Q., Qiu, Y., do Carmo, J.M., Wang, Z., da Silva, A.A., et al. (2021) Direct Cardiac Actions of the Sodium Glucose Co‐Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure‐Overload Heart Failure. Journal of the American Heart Association, 10, e018298. [Google Scholar] [CrossRef] [PubMed]
[21] 周美欣, 楚天舒. 儿茶酚抑素在急性心肌梗死患者交感神经活性中的研究进展[J]. 心血管病学进展, 2020, 41(7): 695-697.
[22] Herat, L.Y., Magno, A.L., Rudnicka, C., Hricova, J., Carnagarin, R., Ward, N.C., et al. (2020) SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection. JACC: Basic to Translational Science, 5, 169-179. [Google Scholar] [CrossRef] [PubMed]
[23] Shimizu, W., Kubota, Y., Hoshika, Y., Mozawa, K., Tara, S., Tokita, Y., et al. (2020) Effects of Empagliflozin versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: The EMBODY Trial. Cardiovascular Diabetology, 19, Article No. 148. [Google Scholar] [CrossRef] [PubMed]
[24] McGuire, D.K., Shih, W.J., Cosentino, F., Charbonnel, B., Cherney, D.Z.I., Dagogo-Jack, S., et al. (2021) Association of SGLT2 Inhibitors with Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes: A Meta-Analysis. JAMA Cardiology, 6, 148-158. [Google Scholar] [CrossRef] [PubMed]
[25] Vaduganathan, M., Docherty, K.F., Claggett, B.L., Jhund, P.S., de Boer, R.A., Hernandez, A.F., et al. (2022) SGLT2 Inhibitors in Patients with Heart Failure: A Comprehensive Meta-Analysis of Five Randomised Controlled Trials. The Lancet, 400, 757-767. [Google Scholar] [CrossRef] [PubMed]

为你推荐